Cite

    Jax, T. et al. (2017). A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovascular diabetology. 16 (1), pp. 1-16. [Online].